FORM 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 31, 2013

 

 

LA JOLLA PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

 

 

 

California   0-24274   33-0361285

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

4370 La Jolla Village Drive, Suite 400,

San Diego, California

   92122
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 207-4264

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 7.01 REGULATION FD DISCLOSURE.

On January 31, 2013, La Jolla Pharmaceutical Company (the “Company”) hosted a presentation at the 2013 Orlando World MoneyShow. The presentation is available on MoneyShow.com for a limited time. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days at http://www.moneyshow.com. A copy of the presentation from the event is attached hereto as Exhibit 99.1 and is also posted on the Company’s website at http://www.ljpc.com/investors-main.html.

The information set forth under Item 7.01 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits. The following exhibit is filed with this report on Form 8-K:

 

Exhibit No.

   

Description

99.1    Presentation used in connection with the 2013 Orlando World MoneyShow January 31, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  LA JOLLA PHARMACEUTICAL COMPANY
Date: February 4, 2013   By:  

/s/ George Tidmarsh

  Name:   George Tidmarsh, M.D., Ph.D.
  Title:   President and Chief Executive Officer

 

-3-